2 results
Approved WMOCompleted
Primary objectivesPhase I:To determine the recommended phase 2 dose (RP2D) of the dacomitinib-PD-0325901 combination in patients with KRASm NSCLC Phase II:To determine the progression free survival of the dacomitinib/PD-0325901 combination compared…
Approved WMORecruiting
To determine the clinical performance of Elecsys® Troponin Ths Gen 6 relative to the clinical diagnosis at different time points after patient admission (T0, T1, T2, T3, T6) using the previously determined universal or combined sex-specific cut-off…